We previously humanized the HER2-targeting scFvs using a human antibody consensus sequence to replace the murine origin scFvs of HER2 (e23sFv), and the results showed that humanized scFvs (P1h2 and P2h2) improved the HER2-targeting and tumor-killing capacities compared to the murine origin antibody (28). This evidence concerns the gene ERBB2 and neoplasm.